Witnessing the stock’s movement on the chart, on Wednesday, Supernus Pharmaceuticals Inc (NASDAQ: SUPN) set off with pace as it heaved 4.02% to $51.24, before settling in for the price of $49.26 at the close. Taking a more long-term approach, SUPN posted a 52-week range of $29.16-$57.65.
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was -8.87%. Meanwhile, its Annual Earning per share during the time was -8.87%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -2.79%. This publicly-traded company’s shares outstanding now amounts to $57.12 million, simultaneously with a float of $54.43 million. The organization now has a market capitalization sitting at $2.94 billion. At the time of writing, stock’s 50-day Moving Average stood at $48.39, while the 200-day Moving Average is $40.36.
Supernus Pharmaceuticals Inc (SUPN) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Drug Manufacturers – Specialty & Generic industry. Supernus Pharmaceuticals Inc’s current insider ownership accounts for 5.07%, in contrast to 101.42% institutional ownership. According to the most recent insider trade that took place on Dec 19 ’25, this organization’s SVP, Chief Tech. Ops. Officer sold 20,000 shares at the rate of 50.41, making the entire transaction reach 1,008,150 in total value, affecting insider ownership by 15,496.
Supernus Pharmaceuticals Inc (SUPN) Earnings and Revenue Records
Supernus Pharmaceuticals Inc’s EPS decrease for this current 12-month fiscal period is -2.79% and is forecasted to reach 3.49 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 7.74% through the next 5 years, which can be compared against the -8.87% growth it accomplished over the previous five years trading on the market.
Supernus Pharmaceuticals Inc (NASDAQ: SUPN) Trading Performance Indicators
Let’s observe the current performance indicators for Supernus Pharmaceuticals Inc (SUPN). It’s Quick Ratio in the last reported quarter now stands at 1.56. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 4.31. Similarly, its price to free cash flow for trailing twelve months is now 41.53.
In the same vein, SUPN’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.34, a figure that is expected to reach 0.39 in the next quarter, and analysts are predicting that it will be 3.49 at the market close of one year from today.
Technical Analysis of Supernus Pharmaceuticals Inc (SUPN)
Going through the that latest performance of [Supernus Pharmaceuticals Inc, SUPN]. Its last 5-days volume of 0.48 million was inferior to the volume of 0.52 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 45.64% While, its Average True Range was 66.26.
Raw Stochastic average of Supernus Pharmaceuticals Inc (SUPN) in the period of the previous 100 days is set at 59.60%, which indicates a major fall in contrast to 76.44% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 1.44 that was lower than 1.48 volatility it exhibited in the past 100-days period.
